Company: TYRA
Filing Date: 2025-05-08
Form Type: S-3
Source: 0001193125-25-116008
Chunk: 40

Company: Tyra Biosciences, Inc.
Filing Date: 2025-05-08
Form: S-3
Chunk 40
---
 reduced public company reporting requirements. See
‘‘Prospectus Summary—Implications of Being an Emerging Growth Company and a Smaller Reporting Company” on page 6 of this prospectus.

Investing in our common stock involves a high degree of risk. Before making an investment decision, please read the information under the heading “ Risk Factors” beginning on page 8 of this prospectus and in the documents incorporated by reference into this prospectus.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

TD Cowen

The date of this prospectus is , 2025.

TABLE OF CONTENTS

| ABOUT THIS PROSPECTUS                                 |     |  1 |
| CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS  |     |  2 |
| WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY 
 REFERENCE                                             |     |  3 |
| PROSPECTUS SUMMARY                                    |     |  5 |
| THE OFFERING                                          |     |  7 |
| RISK FACTORS                                          |     |  8 |
| USE OF PROCEEDS                                       |     | 10 |
| DIVIDEND POLICY                                       |     | 11 |
| DILUTION                                              |     | 12 |
| PLAN OF DISTRIBUTION                                  |     | 13 |
| LEGAL MATTERS                                         |     | 15 |
| EXPERTS                                               |     | 15 |

ABOUT THIS PROSPECTUS

This prospectus is part of a registration statement that we filed on Form S-3 with the U.S. Securities and Exchange
Commission (SEC), using a “shelf” registration process. By using a shelf registration statement, we may sell an unspecified amount of securities from time to time. Under this prospectus, we may offer and sell shares of our common stock
having an aggregate offering price of up to $150,000,000 from time to time through TD Cowen acting as our agent or principal at prices and on terms to be determined by market conditions at the time of the offering. The $150,000,000 of shares of our
common stock that may be sold under this prospectus are included in the $500,000,000 of shares of common stock that may be sold under the registration statement.

This prospectus relates to the offering of our common stock. Before buying any